342 related articles for article (PubMed ID: 19934397)
1. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.
Brantley SJ; Oberlies NH; Kroll DJ; Paine MF
J Pharmacol Exp Ther; 2010 Mar; 332(3):1081-7. PubMed ID: 19934397
[TBL] [Abstract][Full Text] [Related]
2. The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.
Albassam AA; Frye RF; Markowitz JS
Chem Biol Interact; 2017 Jun; 271():24-29. PubMed ID: 28457856
[TBL] [Abstract][Full Text] [Related]
3. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle).
Lee DY; Liu Y
J Nat Prod; 2003 Sep; 66(9):1171-4. PubMed ID: 14510591
[TBL] [Abstract][Full Text] [Related]
4. The study of flavonolignan association patterns in fruits of diverging Silybum marianum (L.) Gaertn. chemotypes provides new insights into the silymarin biosynthetic pathway.
Martinelli T; Whittaker A; Benedettelli S; Carboni A; Andrzejewska J
Phytochemistry; 2017 Dec; 144():9-18. PubMed ID: 28863306
[TBL] [Abstract][Full Text] [Related]
5. Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.
Althagafy HS; Graf TN; Sy-Cordero AA; Gufford BT; Paine MF; Wagoner J; Polyak SJ; Croatt MP; Oberlies NH
Bioorg Med Chem; 2013 Jul; 21(13):3919-26. PubMed ID: 23673225
[TBL] [Abstract][Full Text] [Related]
6. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.
Davis-Searles PR; Nakanishi Y; Kim NC; Graf TN; Oberlies NH; Wani MC; Wall ME; Agarwal R; Kroll DJ
Cancer Res; 2005 May; 65(10):4448-57. PubMed ID: 15899838
[TBL] [Abstract][Full Text] [Related]
7. A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors.
Brantley SJ; Graf TN; Oberlies NH; Paine MF
Drug Metab Dispos; 2013 Sep; 41(9):1662-70. PubMed ID: 23801821
[TBL] [Abstract][Full Text] [Related]
8. The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.
Kawaguchi-Suzuki M; Frye RF; Zhu HJ; Brinda BJ; Chavin KD; Bernstein HJ; Markowitz JS
Drug Metab Dispos; 2014 Oct; 42(10):1611-6. PubMed ID: 25028567
[TBL] [Abstract][Full Text] [Related]
9. Absolute configuration of isosilybin A by X-ray crystallography of the heavy atom analogue 7-(4-Bromobenzoyl)isosilybin A.
Sy-Cordero AA; Day CS; Oberlies NH
J Nat Prod; 2012 Nov; 75(11):1879-81. PubMed ID: 23116206
[TBL] [Abstract][Full Text] [Related]
10. In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction.
Yamaori S; Takami K; Shiozawa A; Sakuyama K; Matsuzawa N; Ohmori S
Biol Pharm Bull; 2015; 38(3):441-7. PubMed ID: 25757926
[TBL] [Abstract][Full Text] [Related]
11. Enhanced bioactivity of silybin B methylation products.
Sy-Cordero AA; Graf TN; Runyon SP; Wani MC; Kroll DJ; Agarwal R; Brantley SJ; Paine MF; Polyak SJ; Oberlies NH
Bioorg Med Chem; 2013 Feb; 21(3):742-7. PubMed ID: 23260576
[TBL] [Abstract][Full Text] [Related]
12. Chemotaxonomic and biosynthetic relationships between flavonolignans produced by Silybum marianum populations.
AbouZid SF; Ahmed HS; Moawad AS; Owis AI; Chen SN; Nachtergael A; McAlpine JB; Brent Friesen J; Pauli GF
Fitoterapia; 2017 Jun; 119():175-184. PubMed ID: 28392269
[TBL] [Abstract][Full Text] [Related]
13. An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.
Zhu HJ; Brinda BJ; Chavin KD; Bernstein HJ; Patrick KS; Markowitz JS
Drug Metab Dispos; 2013 Sep; 41(9):1679-85. PubMed ID: 23835761
[TBL] [Abstract][Full Text] [Related]
14. Identification of UDP-glucuronosyltransferases involved in the metabolism of silymarin flavonolignans.
Vrba J; Papoušková B; Lněničková K; Kosina P; Křen V; Ulrichová J
J Pharm Biomed Anal; 2020 Jan; 178():112972. PubMed ID: 31727359
[TBL] [Abstract][Full Text] [Related]
15. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
Jones DR; Kim SY; Guderyon M; Yun CH; Moran JH; Miller GP
Chem Res Toxicol; 2010 May; 23(5):939-45. PubMed ID: 20429590
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity.
Mooiman KD; Goey AK; Huijbregts TJ; Maas-Bakker RF; Beijnen JH; Schellens JH; Meijerman I
J Pharm Pharmacol; 2014 Sep; 66(9):1339-46. PubMed ID: 24730468
[TBL] [Abstract][Full Text] [Related]
17. Variation in the flavonolignan composition of fruits from different Silybum marianum chemotypes and suspension cultures derived therefrom.
Poppe L; Petersen M
Phytochemistry; 2016 Nov; 131():68-75. PubMed ID: 27639292
[TBL] [Abstract][Full Text] [Related]
18. Silybin is metabolized by cytochrome P450 2C8 in vitro.
Jancová P; Anzenbacherová E; Papousková B; Lemr K; Luzná P; Veinlichová A; Anzenbacher P; Simánek V
Drug Metab Dispos; 2007 Nov; 35(11):2035-9. PubMed ID: 17670841
[TBL] [Abstract][Full Text] [Related]
19. Flavonolignans from Aspergillus iizukae, a fungal endophyte of milk thistle (Silybum marianum).
El-Elimat T; Raja HA; Graf TN; Faeth SH; Cech NB; Oberlies NH
J Nat Prod; 2014 Feb; 77(2):193-9. PubMed ID: 24456525
[TBL] [Abstract][Full Text] [Related]
20. Effect of ethanol on S-warfarin and diclofenac metabolism by recombinant human CYP2C9.1.
Tatsumi A; Ikegami Y; Morii R; Sugiyama M; Kadobayashi M; Iwakawa S
Biol Pharm Bull; 2009 Mar; 32(3):517-9. PubMed ID: 19252308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
